Opinion|Videos|May 29, 2025
CRS Recognition and Intervention: Timing and Clinical Features
Panelists discuss how recognizing and grading cytokine release syndrome (CRS) based on symptoms ranging from mild flulike effects to life-threatening conditions is essential for timely intervention, with early detection being key to managing CRS effectively and preventing progression to severe stages.
Advertisement
Episodes in this series
Summary for Physicians:
Cytokine Release Syndrome (CRS) Recognition and Intervention
- CRS recognition:
- Commonly occurs within 24 to 48 hours post infusion.
- Symptoms include fever, chills, tachycardia, hypotension, dyspnea, and rash.
- Grading CRS:
- Grade 1: Mild fever and flulike symptoms, manageable with supportive care
- Grade 2: Moderate symptoms (eg, hypotension), requires medical intervention (eg, fluids, antipyretics)
- Grade 3: Severe symptoms (eg, hypoxia, multiorgan involvement), requires steroids and possibly tocilizumab
- Grade 4: Life-threatening, requires emergency management and intensive care unit care
- Intervention:
- Grade 1: Symptom management (eg, acetaminophen, hydration)
- Grade 2: Intravenous fluids, antipyretics, monitoring
- Grade 3/4: Corticosteroids, tocilizumab (IL-6 inhibitor), and intensive monitoring
Challenges:
Early recognition is crucial for effective management and preventing progression to severe CRS.
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.
Martin Gleave, CM, MD, FRCSC, FACS, explained how the GUNS trial is using tumor genomics to guide neoadjuvant therapy in high-risk prostate cancer.
Daniel Y.C. Heng, MD, MPH, FRCPC, explained how subsequent therapy and durable responses may have shaped overall survival results in LITESPARK-011.
Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.
Arturo Loaiza-Bonilla, MD, MSEd, FACP, co-founder of Massive Bio and system-wide chief of hematology and oncology at St. Luke’s, explains how AI is matching patients to clinical trials, where the technology falls short, and why he left academia to build what oncology was missing.
The FDA granted RMAT and fast track designations to prizlon-cel, a CD20/CD19 CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.
Findings from the phase 3 VOLGA trial support the FDA approval of perioperative durvalumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
3
Managing Emergencies During Outpatient Bispecific Step-Up Dosing
4
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
5